Marrying Complex Biomarker Validation & CDx Development for Supercharged Precision Oncology Pipeline Commercialization

The 12th World Clinical Biomarkers & CDx Summit returns at a crucial time for the entire precision & targeted drug development industry. Spurred on by a number of recent exciting biomarker-driven therapy and CDx approvals by the FDA, including Eli Lilly’s Verzenio, J&J’s Amivantamab & Takeda’s Mobocertinib, the race to market is becoming ever fiercer to deliver the next-generation of safer & more effective therapies for defined patient populations.

Returning in-person for the first time in three years, hear the latest insights, case studies and technologies enhancing your predictive biomarker discovery, to support next generation CDx development, informed clinical decisions, regulatory approval & a robust go-to market strategy for a breakthrough therapy.

Across 2-days & 3 distinct tracks, this is your only end-to-end biomarker-driven & diagnostic enabled drug development summit, led by 70+ industry leaders triumphing and overcoming challenges to predictive biomarker development and commercialization.

You cannot afford to miss World CB & CDx 2022, as key industry stakeholders gather and leave no stone unturned to advance more life changing precision and targeted drugs to patients.

100+ Expert Speakers Including:

Sarah Hersey

Vice President, Precision Medicine

Bristol Myers Squibb

Silva Krause

Senior Director, Clinical Biomarkers

Vertex Pharmaceuticals

Partha Das

GMD Precision Medicine and Pipeline

The Janssen Pharmaceutical Companies of Johnson & Johnson

Shirin Khambata Ford

Vice President, Head Companion Diagnostics, Global Companion Diagnostics, Global Oncology R&D

Daiichi Sankyo

Lakshman Ramamurthy

Head of Global Regulatory Affairs, Precision Medicine & Digital Health

GlaxoSmithKline

Zhen Su

Chief Executive Officer

Marengo Therapeutics

Michael Lahn

Chief Executive Officer

iOnctura

Minghao Song

Director, Precision Medicine Lead

AstraZeneca

James Hewitt

IVD Product Expert

TÜV SÜD

Meijuan Li

Vice President, Head of Biostatistics, Oncology Group

Eisai

Srinivas Venkatram

Director, CDx Strategy

AbbVie

Pamela Ebrahimi

Deputy Branch Chief, Molecular Genetics Branch

CDRH, U.S. Food and Drug Administration

Geoff Oxnard, MD

VP, Head of Clinical Development

Foundation Medicine

Jena Giltnane

Research Director of Digital & Spatial Pathology

Genentech

Mary Thanh Hai

Deputy Director for Clinical, Office of New Drugs

U.S. Food and Drug Administration

Why Are Experts Attending in 2022?

"I’m looking forward to attending and presenting at the 12th World Clinical Biomarkers & CDx Summit.  This is a key meeting for researchers, biomarker developers and Pharma to connect and shape the future of Precision Medicine."

Amy Gorman, Director, Global Commercial Strategy, Precision Medicine, Janssen

Amy Gorman
Melinda Day

“The Summit uniquely covers the entirety of biomarker discovery and clinical implementation, providing interesting discussions for a wide audience.”

Melinda Day, Associate Director, Translational Clinical Development, Kronos Bio

"This conference has been very insightful in the past as the field of CDx is still advancing and we can learn from each other’s experiences"

Silva Krause, Senior Director, Clinical Biomarkers, Vertex Pharmaceuticals

Silva Krause

View the Full Event Guide Now!

Download your copy to find the 2022 speakers, full agenda breakdown, partners, accessing the best possible rates and to see how biopharma & academia can secure their FREE pass